Predictor Factors for Treatment Failure among Patients on Second Line Antiretroviral Therapy

Authors: Mohd. A. M. Rahim, Yahaya Hassan, Mathumalar L. Fahrni

Abstract:

Second line antiretroviral therapy (ART) regimen is used when patients fail their first line regimen. There are many factors such as non-adherence, drug resistance as well as virological and immunological failure that lead to second line highly active antiretroviral therapy (HAART) regimen treatment failure. This study was aimed at determining predictor factors to treatment failure with second line HAART and analyzing median survival time. An observational, retrospective study was conducted in Sungai Buloh Hospital (HSB) to assess current status of HIV patients treated with second line HAART regimen. Convenience sampling was used and 104 patients were included based on the study’s inclusion and exclusion criteria. Data was collected for six months i.e. from July until December 2013. Data was then analysed using SPSS version 18. Kaplan-Meier and Cox regression analyses were used to measure median survival times and predictor factors for treatment failure. The study population consisted mainly of male subjects, aged 30- 45 years, who were heterosexual, and had HIV infection for less than 6 years. The most common second line HAART regimen given was lopinavir/ritonavir (LPV/r)-based combination. Kaplan-Meier analysis showed that patients on LPV/r demonstrated longer median survival times than patients on indinavir/ritonavir (IDV/r) based combination (p<0.001). The commonest reason for a treatment to fail with second line HAART was non-adherence. Based on Cox regression analysis, other predictor factors for treatment failure with second line HAART regimen were age and mode of HIV transmission.

Keywords: Adherence, antiretroviral therapy, second line, treatment failure.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1096213

References:

[1] Global AIDS response progress report. http://www.unaids.org/en/ dataanalysis/knowyourresponse/countryprogressreports/2012countries/c e_MY_Narrative_Report.pdf (2012, assessed 29 March 2014).
[2] Malaysia Ministry of Health. Guidelines for the management of adult HIV infection with antiretroviral therapy. http://www.moh.gov.my/ images/gallery/Garispanduan/HIVGUIDELINES.pdf (2011, assessed 30 December 2013).
[3] Malaysia Ministry of Health. Country Health Plan 2011-2015, 10th Malaysia Plan. http://www.moh.gov.my/images/gallery/Report/ Country_health.pdf (2012, assessed 29 March 2014).
[4] R. Manfredi, F. Chiodo, "Limits of deep salvage antiretroviral therapy with nelfinavir plus either efavirenz or nevirapine, in highly pre-treated patients with HIV disease,” International journal of antimicrobial agents,vol. 17, issue 6, pp. 431-548, June 2001.
[5] Clinical protocol for the WHO Europian region. Patient evaluation and antiretroviral treatment for adults and adolescents. http://www.euro.who.int/__data/assets/pdf_file/0019/78112/E90840_Ch apter_1.pdf (2012, assessed 29 July 2014).
[6] MSF access campaign Switzerland. Untangling the web of antiretroviral price reductions. http://www.msfaccess.org/sites/default/files/ MSF_UTW_17th_Edition_4_b.pdf (2014, assessed 20 July 2014).
[7] M. Pujades-Rodríguez, D. O'Brien, P. Humblet, A. Calmy, "Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières,” Aids, vol. 11, issue 22, pp.1305-12. July 2008.
[8] E. Humphreys, L Chang, J Harris, "Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy,” Cochrane Database of Systematic Review, vol. 16, issue 6, Jun 2010.
[9] R. Gupta, M. Jordan, B. Sultan, A. Hill, D. Davis, J. Gregson et al, "Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis,” Lancet,vol. 380, issue 9849, pp. 1250-8, Oct 2012.
[10] World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. http://www.who.int/hiv/pub/arv/adult2010/en/ (2010, assessed 29 March 2014).
[11] J. Molina, J. Andrade-Villanueva,J. Echevarria, P. Chetchotisak, J. Corral, N. David et al,"Once-daily atazanavir/ritonavir versus twicedaily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study,” Lancet, vol. 372, issue 9639, pp. 646-55, 2008.
[12] R. Ortiz, E. Dejesus, H. Khanlou, E. Voronin, J. van Lunzen, J. Andrade-Villanueva et al,"Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment naive HIV-1- infected patients at week 48,”AIDS, vol. 22, issue 12, pp. 1389-97, 2008.
[13] K. Smith, W. Weinberg, E. Dejesus, M. Fischl, Q. Liao, L. Ross et al, "Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT,”AIDS Research and Therapy; vol. 5, issue 5, March 2008.
[14] A. Mills,M. Nelson, D. Jayaweera, K. Ruxrungtham, I. Cassetti, P. Girard et al,"Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96- week analysis,” AIDS,vol. 23, issue 13, pp. 1679-88. 2009.
[15] A. Jarez-Garcia, G. Martinez-Rivera, B. Donato,"Cost-effectiveness of atazanavir/ritonavir (Atv+Rtv) compared with lopinavir/ritonavir (Lpv+Rtv) in treatment-naïve Hiv-infected patients in Mexico: a model based on the Castle Study,”Value in Health, vol. 14, issue 3, pp. A117– 8, 2011.
[16] K. Simpson, R. Baran,B. Dietz, "Economic and health related quality of life (HRQL) comparison of lopinavir/ritonavir (LPV/R) and atazanavir plus ritonavir (ATV+RTV)-based regimens for antiretroviral (ARV) experienced Brazilian patients,”Value in Health, vol. 14, issue 7, pp. A270, 2011.
[17] M. Bongiovanni, P. Cicconi,S. Landonio, P. Meraviglia,L. Testa, A. Di Biagio et al, "Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals,”International journal of antimicrobial agents, vol. 26, issue 1, pp. 88–91, 2005.
[18] W. Manosuthi, S. Sungkanuparph, "Effectiveness and metabolic complications after 96 weeks of a generic fixed-dose combination of stavudine, lamivudine , and nevirapine among antiretroviral-naive advanced HIV-infected patients in Thailand: a prospective study,” Current Therapeutic Research, Clinical and Experimental, vol. 69, issue 1, pp. 90–100. Feb 2008.
[19] D. Paterson, S. Swindells, J. Mohr,"Adherence to protease inhibitor therapy and outcomes in patients with HIV infection,”Annalsof Internal Medicine, vol. 133, pp. 21-30, 2000.
[20] M. Bongiovanni, T. Bini,E. Chiesa,P. Cicconi, P,F. Adorni, A. d’Arminio, "Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects,”Antiviral research, vol. 62, issue 1, pp. 53–6. 2004
[21] P. Barreiro,N. Camino,C. de Mendoza, L. Valer,M. Núñez, "Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors,” International journal of antimicrobial agents, vol. 20, issue 6, pp. 438– 43, 2002.
[22] A. Phillips,C. Leen, A. Wilson,J. Anderson, D. Dunn, "Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study,”Lancet, vol. 370, issue 9603, pp. 1923–8. 2007.